An Phase 1 Study to Evaluate the Pharmacokinetic (PK) Profile of FDL169 New Formulations in Healthy Subjects
Status:
Completed
Trial end date:
2018-01-15
Target enrollment:
Participant gender:
Summary
Two parts, two periods, crossover study with part 2 is optional. In both parts, subjects will
be randomized to sequentially receive both sublingual and oral formulations of FDL169.